Navigation Links
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
Date:6/22/2009

/p>

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. NeurogesX submitted a new drug application (NDA) for Qutenza to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the
'/>"/>

SOURCE NeurogesX, Inc.; Astellas Pharma Europe Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. NeurogesX Reports Fourth Quarter and Year-End 2008 Results
2. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
3. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
4. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
5. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
6. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
7. Astellas Names Head of Global R&D Operations
8. Astellas Adds CNS Therapy Area Leader to Global R&D Team
9. Astellas Hires New Vice President of Compliance
10. Astellas Announces New Vice President of Marketing
11. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)...most popular and addictive game, SplitWords, is no... Mountain View, CA (PRWEB) Novem...ictive game, SplitWords, is now available on the i...elp banish that ,tip of the tongue, syndrome forev...nges the brain by encouraging users to form comple...
(Date:11/21/2009)...ask whether there is a secret to ,alcohol rehab su... London, UK (PRWEB) November 21, 2009 -- Li... the adult UK population drinking enough alcohol t...r disease*, it is hardly a surprise that many are ...and residential centres for help. However, for som...
(Date:11/20/2009)...wire-USNewswire/ -- The American Academy of Actua...eform legislation released this week to contain st...idual coverage mandate. The actuaries said that an...dverse selection stemming from more restrictive is... "The individual mandate language should be streng...
(Date:11/20/2009)...ongressmen in Competitive Re-election Battles Coul... Washington, DC (Vocus) Novemb...r re-election next year in races deemed to be comp...o regret voting for House Speaker Nancy Pelosi&rsq...by International/ O’Leary Report poll. (Th...
(Date:11/20/2009)...wire-FirstCall/ -- Centene Corporation (NYSE: ...Bank of America Merrill Lynch 2009 Credit Conferen...laza Hotel Times Square in New York City. ,, Ce... a.m. Eastern Time. Investors and other interested...ne,s presentation at: http://www.veracast.com/web...
Breaking Medicine News(10 mins):Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3
... a new study, nearly one third of a group of patie...even though it was likely to worsen their conditio... factors for head and neck cancer especially in co...p of 70 patients with head and neck cancer, one th...
...treatment for smallpox, which kills about 30% of i... giving a vaccine within days of exposure can prot... to donate up to 90 million doses of decades-old s...es has been working to gather enough doses of smal...
...tal estrogen lotion appears to reduce the number o...ording to results from a pivotal-stage trial of th...ities, it would be the first estrogen replacement ... of hot flashes during the course of the 16-week t...
... researchers in Dallas, using disinfectant gels, r...y lead to a decrease in hygiene. Getting doctors a... is thought to be a major advance in reducing hosp...uming, the rubs are drying to the skin. That...
...leepwalk are more likely to have a specific geneti...e who do not. Sleepwalking in adults is quite diff...ely to lead to injury or violent behaviour, and th...variation in these patients. Genetic testing...
...loss is often an indicator of Alzheimer's disease ...e has been a lot of controversy over the implicati...nd certain other aspects of mental function,// lik... also the view that it's a disease in its own righ...
Other Medicine News:
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstC...ounced results for its first quarter ended Septemb...4 per diluted share, on revenues of $3,263,000. T... per diluted share, on revenues of $3,168,000 for ...n the first quarter results, Biotel President and ...
(Date:11/20/2009)..., , PLYMOUTH MEETING, Pa., Nov. 20 /PRN...w York Times article that questions why currently...nt some cancers are being ignored, ECRI Institute,...g a roadmap to the evidence on Finasteride for Pr...,, The November 13, 2009, New York Times arti...
(Date:11/20/2009)..., , MEMPHIS, Tenn., Nov. 20 /PRNewswire-F...thopaedics Division is pleased to announce the sig... United States Department of Defense that may lead...ended to revolutionize the treatment of the limbs ..., Last year, the Defense Advanced Research Project...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4New Fertility Financing for Donated Eggs Fills Void Left by Capital One 51716 1New Fertility Financing for Donated Eggs Fills Void Left by Capital One 51716 2Educated Parkinsons Patients Move to Meds Sooner 51713 1Educated Parkinsons Patients Move to Meds Sooner 51713 2Exponent to Announce Second Quarter 2009 Results 51709 1
...preclinical data presented by Dr. Peter Jones, Dir...cer Center, SAN FRANCISCO, Oct. 25 SuperGen Inc....d to the discovery, rapid,development and commerci...logical malignancies, today announced as part of a...C International Conference that,S110, the Company,...
...y Published in Neurogastroenterology and Motility-...Inc. (AMEX: SYI ) announced today the publication...its compound, alagebrium, to,reduce serum levels o...e,neuronal nitric oxide synthase (nNOS) activity i...S activity is one of the major putative mechanisms...
Other Medicine Technology:SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session 2SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session 3Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications 2Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications 3Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications 4
...rews with NeedlePunch Needles are ideal for arthro...ment. The NeedlePunch Needles are preloaded on one...haft. As the anchor is being inserted, ensure the ...ng the handle to ensure suture slide ability for e...
FiberWire® Suture Kit
FiberSnare™
Flowstar Uroflowmeter
Medicine Products: